Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 18September 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023...
Nasdaq GlobeNewswire
18/09/2023

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development…

BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of vaccine candidatesData generated by this partnership will contribute to CEPI's 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against future viral threats with pandemic potentialThe partnership is part of...
Nasdaq GlobeNewswire
18/09/2023

Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC…

Dr. Xiao Shen, founder and CEO of Canton Biologics , said, "I am deeply grateful to the investors in this round for recognizing Canton Biologics' technical expertise and growth potential. From our inception, we've been anchored by values of 'reliability, efficiency, and innovation', and inspired by our vision of empowering future with biotechnology. This financing round will further bolster our progress in biotechnological R&D, strengthen our global presence, perpetually support our…
PR Newswire
18/09/2023

Crown Aesthetics Announces Launch Expansion of BIOJUVE™ Living Skin Biome Care…

"We're thrilled to be able to introduce our latest innovation, BIOJUVE, to UKI and German markets," said Michael McKenna, Executive Vice President and General Manager of Crown Aesthetics. "The brand has enjoyed tremendous success since it first launched in the US at the beginning of 2023. It quickly gained momentum with several notable dermatologists signing on as early adopters. We're looking forward to the brand's international expansion and to educating consumers worldwide…
PR Newswire
18/09/2023

Diagnostic Imaging Market worth $34.6 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=411 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=411 Browse in-depth TOC on "Diagnostic Imaging Market" 400 - Tables 47 - Figures 395 - Pages Diagnostic Imaging Market Scope: Mammography systems segment to register significant growth rate over the forecast period of 2023-2028. Based on the product, the global diagnostic...
PR Newswire
18/09/2023

Field Medical, Inc. Announces Oversubscribed Seed Round to Advance…

The convertible note funding was led by private investors who were joined by multiple strategic investors. This financing will support preclinical-to-clinical development activities including first-in-human studies planned for early 2024. The convertible note funding was led by private investors who were joined by multiple strategic investors. This financing will support preclinical-to-clinical development activities including first-in-human studies planned for early 2024. Field Medical is...
PR Newswire
18/09/2023

AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors

Dr. Kaplan serves as a director of Nicox Inc. which acquired Aciex Therapeutics, Inc. in 2014 when he was Executive Chair. He is an independent board member of Beacon Therapeutics. Dr. Kaplan has served on the boards Acadia Pharmaceuticals, Acucela Inc., Altheos (Executive Chair), Neurotech, Oculex and National Neurovision Research Institute (FFB). He is a former trustee of the Keck Graduate Institute and former member of the Scientific Advisory Board of Bay City Capital. Dr. Kaplan...
Nasdaq GlobeNewswire
18/09/2023

Broncus Announced Long-Term Follow-Up Data on InterVapor, Showing Stable…

The follow-up data show that no serious adverse events associated with InterVapor® were reported after BTVA treatment. The 36-month efficacy data suggest that patients' pulmonary function, exercise tolerance, and symptom score showed better benefits compared with those treated with standard medications. And the development trend of lung diseases in patients showed decline. These facts well verified long-term safety and stable efficacy of BTVA. The follow-up data show that no serious adverse...
PR Newswire
18/09/2023

MAR Weekly Report_VIRBAC SA_11 to 15 September 2023

Statement of transactions in own shares from September 11, 2023 to September 15, 2023BNP PARIBAS EXANE Aggregated presentation by day and by market Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price...
Nasdaq GlobeNewswire
18/09/2023

Kidney Function Test Market to Earn Massive Revenue by 2029 | Brandessence…

The business intelligence report on this market offers a deep dive assessment of the top factors influencing the expansion trajectory of this industry. Growth drivers, restraints, challenges, and opportunities pertaining to this industry are well elaborated in this marketspace. It also offers a 360-degree outlook of the top market segments and geographical landscape with accurate growth projections of each region, country, and niche segments. Apart from that, it highlights each player operating…
PR Newswire
18/09/2023

PLUSS ties up with The Rodnight Partnership to enhance availability of its…

MiraCradle® has also been included in the WHO compendium of 'Affordable Innovative Health Technologies' and has been granted a patent in the United States, Europe, Brazil, South Africa, Malaysia and India. Its development team members have received MIT's 'Innovators Under 35' award. MiraCradle® has also been included in the WHO compendium of 'Affordable Innovative Health Technologies' and has been granted a patent inthe United States,Europe,Brazil,South Africa,MalaysiaandIndia...
PR Newswire
18/09/2023

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue…

If approved OX124 will meet the significant and growing need of more powerful rescue medications improving the possibility to revive individuals who have got an overdose caused by use of synthetic opioids, such as fentanyl. During the latest 12-month period, ending April 2023, the predicted annual number of fatal overdoses in the US counted for more than 110.000.[2] The great majority, 76 percent, refers to opioid overdoses, and of these 91 percent involved synthetic opioids.[3] If approved...
PR Newswire
18/09/2023

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to…

In France, approximately 2 to 6 million individuals are affected by influenza annually, leading to over 20,000 hospitalizations and 10,000 excess deaths, 90% of which occur in older adults.1 A new analysis spotlights how influenza vaccines can offer a powerful prevention tool that reduces healthcare resource use.1 Findings from a dynamic transmission model indicated that standard-dose quadrivalent influenza vaccines for this demographic could reduce hospitalizations by 11.1%-30.0% and ICU…
PR Newswire
18/09/2023

Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program

EUR 3.5 Million in Unconditional FundingAllowing Company to Achieve Topline Data from KALAHARI TrialLeuven, BELGIUM, Boston, MA, US –September 18 , 2023 – 8am CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special...
Nasdaq GlobeNewswire
18/09/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US...
Nasdaq GlobeNewswire
18/09/2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – September 18 , 2023 – 8 .00AM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a first transparency notification on...
Nasdaq GlobeNewswire
18/09/2023

PHAXIAM Therapeutics announces the completion of its reverse share split

PRESS RELEASE PHAXIAM Therapeutics announces the completion of its reverse share splitLyon (France) and Cambridge (MA, US) , September 18 th,2023 - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (the "Company") , announces the completion today of the reverse share split of the shares composing the Company's share capital, as decided by the Executive Director on July 27 th, 2023 , following sub-delegation granted...
Nasdaq GlobeNewswire
18/09/2023

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar…

Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone 1 ,2 Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio Basel, September 18, 2023— Sandoz, a global leader in generic...
Nasdaq GlobeNewswire
18/09/2023

New drug class prevents key ageing mechanism in organ transplants

By transplanting older donor organs into younger recipients, researchers from Harvard Medical School and the Mayo Clinic investigated the role of transplantation in inducing senescence, a biological mechanism linked to ageing and age-related diseases. The researchers conducted age-disparate heart transplants from both young (3 months) and old (18–21 months) mice into younger recipients. Recipients of old hearts showed augmented frequencies of senescent cells in draining lymph nodes, livers, and…
PR Newswire
18/09/2023

SHISEIDO Celebrates Anne Hathaway as VITAL PERFECTION Brand Ambassador New York…

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9201251-shiseido-anne-hathaway-new-vital-perfection-global-ambassador/ Experience the full interactive Multichannel News Release here:https://www.multivu.com/players/English/9201251-shiseido-anne-hathaway-new-vital-perfection-global-ambassador/ "New Yorkis a significant place where our relationship with Anne began, and it has been nothing short of an inspiring journey. Anne...
PR Newswire
16/09/2023

HUMAN APPEAL SENDS AID TO LIBYA TO AVERT HUNGER AND DISEASE FROM DEADLY FLOODING

Many of Libya's eastern towns have been affected but in Bayda and Derna the devastation is cataclysmic. In the port city of Derna, home to 100,000 people, entire communities have been washed away after two dams collapsed. Many ofLibya'seastern towns have been affected but in Bayda and Derna the devastation is cataclysmic. In the port city of Derna, home to 100,000 people, entire communities have been washed away after two dams collapsed. The humanitarian situation on the ground is tragic...
PR Newswire
15/09/2023

Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to…

About Dr.Joseph V. Pergolizzi, Jr., M.D., M.B.A. Dr. Pergolizzi has extensive academic, clinical, and business achievements related to his lifelong interest in advancing medical science and the practice of modern global healthcare. He has gained a strong reputation as an experienced, results-oriented C-level leader with a particular focus on new companies. He has held various C-level positions in private and public companies. He can leverage his significant medical expertise,...
PR Newswire
15/09/2023

Progress share buy-back program Fagron

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 15 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 11 September 2023 through 15 September 2023, Fagron purchased 27,000 of its owns shares at an average price of €16.81 per share corresponding to a total amount of €453,745.66. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron's obligations under its long term incentive scheme,...
Nasdaq GlobeNewswire
15/09/2023

LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED…

The Arrangement remains subject to the satisfaction or waiver of certain other closing conditions customary in a transaction of this nature, including the receipt of a final order from the Ontario Superior Court of Justice (Commercial List) approving the Arrangement (the "Final Order"). The hearing in respect of the Final Order is scheduled to take place on September 19, 2023. Assuming that these remaining conditions to closing are satisfied, the Arrangement is expected to close at or…
PR Newswire
15/09/2023
Altri  Comunicati